AYTU BioPharma financials
$2.20+1.38%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '26 Jun 30 | Q3 '26 Mar 31 | Q2 '26 Dec 31 | Q1 '26 Sep 30 | Q4 '25 Jun 30 | Q3 '25 Mar 31 | Q2 '25 Dec 31 | Q1 '25 Sep 30 | Q4 '24 Jun 30 | Q3 '24 Mar 31 | Q2 '24 Dec 31 | Q1 '24 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.1M | $12.4M | $15.2M | $13.9M | $15.1M | $18.5M | $16.2M | $16.6M | $14.6M | $14.0M | $18.7M | $17.8M |
| Gross profit | $10.4M | $7.6M | $9.6M | $9.2M | $10.3M | $12.8M | $10.8M | $12.0M | $11.1M | $10.4M | $14.6M | $13.0M |
| Gross margin | 64.6% | 61.2% | 63.5% | 66.1% | 67.8% | 69.4% | 66.5% | 72.3% | 75.7% | 73.9% | 77.9% | 73.2% |
| Operating income | -$777.0K | -$4.1M | -$2.0M | -$1.5M | -$7.6M | $2.4M | -$1.7M | -$930.0K | -$2.3M | -$1.6M | $3.1M | -$867.0K |
| Net income | -$15.0K | -$5.6M | -$10.6M | $2.0M | -$19.8M | $4.0M | $788.0K | $1.5M | -$4.6M | -$2.9M | -$220.0K | -$8.1M |
| Net margin | −0.1% | −45.3% | −69.8% | 14.1% | −130.9% | 21.6% | 4.9% | 8.9% | −31.6% | −20.6% | −1.2% | −45.6% |
| Diluted EPS | $0.00 | $-0.53 | $-1.05 | $-0.08 | — | $0.21 | $-0.26 | $-0.15 | $-0.82 | $-0.52 | $-0.04 | $-1.48 |
| EBITDA | $344.0K | -$2.9M | -$1.1M | -$701.0K | $2.1M | $3.7M | $914.0K | $1.2M | $1.2M | $180.0K | $4.9M | -$867.0K |
| Operating cash flow | $4.4M | -$4.2M | $3.7M | -$618.0K | $2.8M | -$6.5M | $2.9M | -$1.2M | -$788.0K | -$254.0K | -$135.0K | -$211.0K |
| Free cash flow | $4.4M | -$4.2M | $3.7M | -$618.0K | $2.8M | -$6.5M | $2.9M | -$1.3M | -$1.1M | -$254.0K | -$135.0K | -$211.0K |
| Diluted shares | 9.3M | 10.5M | 10.0M | 19.5M | — | 8.2M | 8.5M | 9.1M | 5.6M | 5.5M | 5.5M | 5.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $26.3M | $26.7M | $30.0M | $32.6M | $31.0M | $18.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $17.0M | $21.8M | $20.9M | $27.2M | $21.8M | $21.4M |
| Total assets | $105.0M | $111.7M | $122.0M | $125.0M | $124.2M | $124.2M |
| Total liabilities | $69.7M | $76.5M | $107.8M | $101.8M | $105.2M | $89.3M |
| Shareholders' equity | $35.3M | $35.1M | $14.2M | $23.2M | $19.0M | $34.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology